Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial

Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial

Background In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once‐weekly resulted in a nonsignificant reduction in major adverse cardiovascular events (MACEs) and a nominal 14% reduction in all‐cause mortality in 14 752 patients with type 2 diabetes mellitus (T2DM) with and...

Full description

Bibliographic Details
Main Authors: Robert J. Mentz, M. Angelyn Bethel, Peter Merrill, Yuliya Lokhnygina, John B. Buse, Juliana C. Chan, João S. Felício, Shaun G. Goodman, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Renato D. Lopes, Aldo P. Maggioni, Peter Öhman, Neha J. Pagidipati, Neil R. Poulter, Ambady Ramachandran, Barry Reicher, Rury R. Holman, Adrian F. Hernandez
Format: Article
Language:English
Published: Wiley 2018-10-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
glucagon‐like peptide‐1 receptor agonis
major adverse cardiac event
mortality
type 2 diabetes mellitus
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.118.009304

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.118.009304

Similar Items